PubMed

Albuminuria in chronic heart failure: prevalence and prognostic importance.

Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ; CHARM Investigators and Committees.

Lancet. 2009 Aug 15;374(9689):543-50.PMID: 19683640 [PubMed - indexed for MEDLINE]Related articles

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, Sattar N; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators.

Diabetes Care. 2009 May;32(5):915-20. Epub 2009 Feb 5.PMID: 19196892 [PubMed - indexed for MEDLINE]Related articlesFree article

Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators.

Eur J Heart Fail. 2009 Feb;11(2):170-7.PMID: 19168515 [PubMed - indexed for MEDLINE]Related articles

Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology.

Syed Z, Scirica BM, Mohanavelu S, Sung P, Michelson EL, Cannon CP, Stone PH, Stultz CM, Guttag JV.

Am J Cardiol. 2009 Feb 1;103(3):307-11. Epub 2008 Nov 19.PMID: 19166680 [PubMed - indexed for MEDLINE]Related articles

Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.

Meredith PA, Ostergren J, Anand I, Puu M, Solomon SD, Michelson EL, Olofsson B, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, McMurray JJ.

J Am Coll Cardiol. 2008 Dec 9;52(24):2000-7.PMID: 19055992 [PubMed - indexed for MEDLINE]Related articles

Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.

Abrahamsson P, Dobson J, Granger CB, McMurray JJ, Michelson EL, Pfeffer M, Pocock S, Solomon SD, Yusuf S, Swedberg K; CHARM Investigators.

Eur Heart J. 2009 Feb;30(3):338-45. Epub 2008 Nov 11.PMID: 19001475 [PubMed - indexed for MEDLINE]Related articles

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.

Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB; CHARM Investigators.

Eur Heart J. 2008 Dec;29(24):3022-8. Epub 2008 Nov 5.PMID: 18987098 [PubMed - indexed for MEDLINE]Related articles

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.

Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, Anker SD, Swedberg KB.

Eur Heart J. 2008 Nov;29(21):2641-50. Epub 2008 Sep 26.PMID: 18819960 [PubMed - indexed for MEDLINE]Related articlesFree article

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators.

Arch Intern Med. 2008 Aug 11;168(15):1699-704.PMID: 18695086 [PubMed - indexed for MEDLINE]Related articlesFree article

An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).

Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S; TROPHY Study Investigators.

J Clin Hypertens (Greenwich). 2008 Jun;10(6):436-42.PMID: 18550933 [PubMed - indexed for MEDLINE]Related articles

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ; CHARM Investigators.

Eur Heart J. 2008 Jun;29(11):1377-85. Epub 2008 Apr 14.PMID: 18413309 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

Weir RA, McMurray JJ, Puu M, Solomon SD, Olofsson B, Granger CB, Yusuf S, Michelson EL, Swedberg K, Pfeffer MA; CHARM Investigators.

Eur J Heart Fail. 2008 Feb;10(2):157-63. Epub 2008 Jan 31.PMID: 18242128 [PubMed - indexed for MEDLINE]Related articles

Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.

Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA; CHARM Program Investigators.

J Am Coll Cardiol. 2007 Nov 13;50(20):1959-66. Epub 2007 Oct 29.PMID: 17996561 [PubMed - indexed for MEDLINE]Related articles

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.

Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA; Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators.

Circulation. 2007 Sep 25;116(13):1482-7. Epub 2007 Aug 27.PMID: 17724259 [PubMed - indexed for MEDLINE]Related articlesFree article

Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, Granger CB, McMurray JJ, Solomon SD; CHARM Investigators.

Circulation. 2007 Aug 7;116(6):627-36. Epub 2007 Jul 16. Erratum in: Circulation. 2007 Aug 7;116(6):e136. PMID: 17638930 [PubMed - indexed for MEDLINE]Related articlesFree article

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.

Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators.

J Am Coll Cardiol. 2007 Jul 3;50(1):40-7. Epub 2007 Jun 18.PMID: 17601544 [PubMed - indexed for MEDLINE]Related articles

Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators.

Circulation. 2007 Jun 19;115(24):3111-20. Epub 2007 Jun 11.PMID: 17562950 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.

Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG; CHARM Investigators and Committees.

Eur J Heart Fail. 2007 May;9(5):510-7. Epub 2007 Feb 20.PMID: 17317308 [PubMed - indexed for MEDLINE]Related articles

Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.

Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators.

Eur J Heart Fail. 2007 Jan;9(1):83-91. Epub 2006 Dec 21.PMID: 17188020 [PubMed - indexed for MEDLINE]Related articles

Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme.

Hawkins NM, Wang D, McMurray JJ, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Pocock SJ, Ostergren J, Michelson EL, Dunn FG; CHARM Investigators and Committees.

Heart. 2007 Jan;93(1):59-64. Epub 2006 Sep 4.PMID: 16952975 [PubMed - indexed for MEDLINE]Related articles

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators.

Am Heart J. 2006 Jul;152(1):86-92.PMID: 16838426 [PubMed - indexed for MEDLINE]Related articles

Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.

Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA; CHARM Investigators.

J Am Coll Cardiol. 2006 May 16;47(10):1997-2004. Epub 2006 Apr 27.PMID: 16697316 [PubMed - indexed for MEDLINE]Related articles

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.

McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators.

Am Heart J. 2006 May;151(5):985-91.PMID: 16644319 [PubMed - indexed for MEDLINE]Related articles

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.

Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S.

Am Heart J. 2006 May;151(5):985-91. Erratum in: Am Heart J. 2006 Aug;152(2):354. PMID: 16644318 [PubMed - indexed for MEDLINE]Related articles

Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA; Trial of Preventing Hypertension (TROPHY) Study Investigators.

N Engl J Med. 2006 Apr 20;354(16):1685-97. Epub 2006 Mar 14.PMID: 16537662 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.

O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators.

Circulation. 2006 Feb 21;113(7):986-94. Epub 2006 Feb 13.PMID: 16476847 [PubMed - indexed for MEDLINE]Related articlesFree article

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.

Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators.

Circulation. 2006 Feb 7;113(5):671-8.PMID: 16461840 [PubMed - indexed for MEDLINE]Related articlesFree article

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.

Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA; CHARM investigators.

Lancet. 2005 Dec 10;366(9502):2005-11.PMID: 16338449 [PubMed - indexed for MEDLINE]Related articles

Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients.

Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA; Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators.

Circulation. 2005 Dec 13;112(24):3738-44. Epub 2005 Dec 5.PMID: 16330684 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S; CHARM Investigators.

JAMA. 2005 Oct 12;294(14):1794-8.PMID: 16219883 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of mortality and morbidity in patients with chronic heart failure.

Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB.

Eur Heart J. 2006 Jan;27(1):65-75. Epub 2005 Oct 11.PMID: 16219658 [PubMed - indexed for MEDLINE]Related articlesFree article

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.

O'Meara E, Lewis E, Granger C, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Ostergren J, Carlsson J, Olofsson B, McMurray J, Yusuf S, Swedberg K, Pfeffer MA.

Eur J Heart Fail. 2005 Jun;7(4):650-6.PMID: 15921807 [PubMed - indexed for MEDLINE]Related articles

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees.

Circulation. 2004 Oct 26;110(17):2618-26. Epub 2004 Oct 18.PMID: 15492298 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.

Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA.

Circulation. 2004 Oct 12;110(15):2180-3. Epub 2004 Oct 4. Erratum in: Circulation. 2005 Jan 25;111(3):378. PMID: 15466644 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):777-81.PMID: 13678871 [PubMed - indexed for MEDLINE]Related articles

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):772-6.PMID: 13678870 [PubMed - indexed for MEDLINE]Related articles

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):767-71.PMID: 13678869 [PubMed - indexed for MEDLINE]Related articles

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.

Lancet. 2003 Sep 6;362(9386):759-66.PMID: 13678868 [PubMed - indexed for MEDLINE]Related articles

Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.

Pepine CJ, Cooper-DeHoff RM, Weiss RJ, Koren M, Bittar N, Thadani U, Minkwitz MC, Michelson EL, Hutchinson HG; Comparative Efficacy and Safety of Nisoldipine and Amlodipine (CESNA-II) Study Investigators.

Am J Cardiol. 2003 Feb 1;91(3):274-9.PMID: 12565082 [PubMed - indexed for MEDLINE]Related articles

The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study.

Haider AW, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA, O'Donnell CJ, Levy D.

J Am Coll Cardiol. 2002 Oct 16;40(8):1408-13.PMID: 12392829 [PubMed - indexed for MEDLINE]Related articles

Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial.

Zyczynski TM, Leidy NK, Kong BW, Helaszek CT, Michelson EL; Association of Black Cardiologists (ABC) Candesartan Study Group.

Heart Dis. 2000 Nov-Dec;2(6):400-6.PMID: 11728290 [PubMed - indexed for MEDLINE]Related articles

The ABC Trial.

Frishman WH, Michelson EL.

Heart Dis. 2000 Nov-Dec;2(6):389-91. No abstract available. PMID: 11728288 [PubMed - indexed for MEDLINE]Related articles

Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group.

Gradman AH, Lewin A, Bowling BT, Tonkon M, Deedwania PC, Kezer AE, Hardison JD, Cushing DJ, Michelson EL.

Heart Dis. 1999 May-Jun;1(2):52-7.PMID: 11720604 [PubMed - indexed for MEDLINE]Related articles

A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II.

Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, Michelson EL, Wang R; CLAIM Study Investigators.

J Hum Hypertens. 2001 Jul;15(7):475-80.PMID: 11464257 [PubMed - indexed for MEDLINE]Related articlesFree article

Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.

Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R; CLAIM Study Investigators.

J Clin Hypertens (Greenwich). 2001 Jan-Feb;3(1):16-21.PMID: 11416677 [PubMed - indexed for MEDLINE]Related articles

The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial.

Neutel JM, Weir MR, Moser M, Harris S, Edwards D, Michelson EL, Wang R, ACTION Study Investigators.

J Clin Hypertens (Greenwich). 2000 May;2(3):181-186.PMID: 11416644 [PubMed - as supplied by publisher]Related articles

Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.

Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY.

Am J Hypertens. 2001 Jun;14(6 Pt 1):567-72.PMID: 11411737 [PubMed - indexed for MEDLINE]Related articles

Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.

Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL; Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.

Am J Cardiol. 2001 Mar 15;87(6):727-31.PMID: 11249891 [PubMed - indexed for MEDLINE]Related articles

Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.

Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, Tudor GE, Swedberg K, Stevenson LW, Califf RM, Pfeffer MA.

Am J Med. 2000 Oct 15;109(6):489-92. No abstract available. PMID: 11042239 [PubMed - indexed for MEDLINE]Related articles

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.

Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, Califf RM, Bart BA, Held P, Michelson EL, Sellers MA, Ohlin G, Sparapani R, Pfeffer MA.

Am Heart J. 2000 Apr;139(4):609-17.PMID: 10740141 [PubMed - indexed for MEDLINE]Related articles